Immunohistochemical analysis of NF-kγB signaling proteins IKKη, p50/;p105, p52/;p100 and RelA in prostate cancers

APMIS

Volumn 117, Issue 8, 2009, Pages 623-628

  Seo, Seong Il ^a   Song, Sang Yong ^a   Kang, Mi Ran ^b   Kim, Min Sung ^b   Oh, Ji Eun ^b   Kim, Yoo Ri ^b   Lee, Ji Youl ^a   Yoo, Nam Jin ^b   Lee, Sug Hyung ^b  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Expression; IKK ; NF B; P50 ; 100; P52 ; p100; Prostate cancer; RelA

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR RELA;

EID: 68349105162     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02506.x     Document Type: Article

References (22)

1. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 2004 6 : 203 8.
2. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappa B. Cell Death Differ 2006 13 : 759 72.
3. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006 25 : 6817 30.
4. Adli M, Baldwin AS. IKK-i/;IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/;RelA phosphorylation. J Biol Chem 2006 281 : 26976 84.
5. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007 129 : 1065 79.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
7. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009 69 : 1243 54.
8. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998 4 : 844 7.
9. Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, et al. Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS 2009 117 : 28 33.
10. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/;Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997 100 : 2952 60.
11. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, et al. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999 18 : 2567 77.
12. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999 5 : 119 27.
13. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997 15 : 1987 94.
14. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr., Kaur P, et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004 10 : 2466 72.
15. Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, et al. TNF/;IL-1/;NIK/;NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 2008 53 : 166 76.
16. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005 93 : 1019 23.
17. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999 18 : 7389 94.
18. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/;p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008 68 : 1725 33.
19. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003 91 : 417 20.
20. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000 157 : 1769 75.
21. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007 12 : 131 44.
22. Courtois G, Gilmore TD. Mutations in the NF-kappa B signaling pathway: implications for human disease. Oncogene 2006 25 : 6831 43.